484 related articles for article (PubMed ID: 25886603)
1. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S
BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
3. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity.
Baumal CR; Goldberg RA; Fein JG
Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):432-8. PubMed ID: 25970863
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
[TBL] [Abstract][Full Text] [Related]
5. Spectral-Domain OCT Analyses of Macular Changes After Ranibizumab Therapy for Type 1 Retinopathy of Prematurity.
Erol MK; Coban DT; Özdemir Ö; Tunay ZÖ; Bilgin AB; Dogan B
J Pediatr Ophthalmol Strabismus; 2015; 52(3):152-8. PubMed ID: 25859685
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Chandra P
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC
Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921
[TBL] [Abstract][Full Text] [Related]
8. [The clinical study on intravitreous injection of ranibizumab for aggressive posterior retinopathy of prematurity].
Tian R; Zhang G; Tang S; Guo J; Tan W
Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):822-5. PubMed ID: 26850583
[TBL] [Abstract][Full Text] [Related]
9. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy.
Chan JJT; Lam CPS; Kwok MKM; Wong RLM; Lee GKY; Lau WWY; Yam JCS
Sci Rep; 2016 Jun; 6():27082. PubMed ID: 27256987
[TBL] [Abstract][Full Text] [Related]
10. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity.
Castellanos MA; Schwartz S; García-Aguirre G; Quiroz-Mercado H
Br J Ophthalmol; 2013 Jul; 97(7):816-9. PubMed ID: 23221964
[TBL] [Abstract][Full Text] [Related]
11. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.
Sahinoglu-Keskek N; Akkoyun I; Torer B
Eur J Ophthalmol; 2021 Jan; 31(1):179-183. PubMed ID: 31718282
[TBL] [Abstract][Full Text] [Related]
12. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
[TBL] [Abstract][Full Text] [Related]
14. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
15. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
Harper CA; Wright LM; Young RC; Read SP; Chang EY
Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
[TBL] [Abstract][Full Text] [Related]
16. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
Chandra P; Kumawat D; Agarwal D; Chawla R
J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
[TBL] [Abstract][Full Text] [Related]
17. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.
Huang Q; Zhang Q; Fei P; Xu Y; Lyu J; Ji X; Peng J; Li YA; Zhao P
Ophthalmology; 2017 Aug; 124(8):1156-1164. PubMed ID: 28412066
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
[TBL] [Abstract][Full Text] [Related]
20. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
Kim J; Kim SJ; Chang YS; Park WS
Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
